Skip to content
lifestyle.goodsciencing.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
ELI LILLY AND COMPANY
Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
June 14, 2026
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
June 13, 2026
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
June 10, 2026
FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
June 9, 2026
Lilly’s oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials
June 9, 2026
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
May 22, 2026
Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
May 21, 2026
Lilly to participate in Bernstein’s 42nd Annual Strategic Decisions Conference
May 18, 2026
Lilly and UNICEF collaborate to give millions of children a healthier start
May 14, 2026
Lilly’s Foundayo and lower-dose Zepbound helped people maintain weight loss after switching from higher doses of injectable incretin therapy in two late-phase trials
May 13, 2026
1
2
3
…
5
Next Page
→